Power morcellators are used in gynecological surgeries like hysterectomies or fibroid removals to cut into tumors and suck them away. Problem is, the device may not thoroughly remove the cells, tissues and tumors — meaning bits of a tumor could be cut away from one spot and, instead of being removed, move and settle down in another section of the uterine area. If the tumor in question is benign, that is not a big deal. But if the tumor in question is cancerous, well, that means a woman could potentially face a cancerous growth in a completely unexpected area.
While women undergo pre-operative tests and screenings to rule out cancer, that is not always possible to know. Some malignant tumors are not capable of being identified until after surgery; once the removed specimen is sent to pathology for testing.
But here’s what we do know:
- Pharmaceutical companies that manufacture and market power morcellators have been aware of the device’s risk of spreading cancerous tumors and cells for some time now; and
- Our knowledge of the risk that women may have cancerous tumors that cannot be identified before surgery is growing by the month.
If there is a risk that there are cancerous tumors that cannot be identified prior to surgery and you couple that with the fact that minimally invasive hysterectomies and fibroid removals are commonly performed with power morcellators, you have a situation prime for the spread of cancer in a woman’s abdominal and pelvic region.
Which is where our power morcellator lawsuit comes in. Manufacturers who knew of the risks should have done more to help female patients and their doctors.
If you or someone you know has developed cancer or unexpected fibroids after having gynecological surgery, a power morcellator device could be to blame.